Traditional Chinese Medicine Use in the Treatment of Acute Heart Failure in Western Medicine Hospitals in China: Analysis From the China PEACE Retrospective Heart Failure Study

Author:

Yu Yuan12,Spatz Erica S.34,Tan Qi56,Liu Shuling3,Lu Yuan3,Masoudi Frederick A.7,Schulz Wade L.38,Krumholz Harlan M.349,Li Jing12,

Affiliation:

1. The China PEACE Collaborative Group: NHC Key Laboratory of Clinical Research for Cardiovascular Medications National Clinical Research Center of Cardiovascular Diseases, Fuwai Hospital National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

2. Central China Subcenter of the National Center for Cardiovascular Diseases Henan People's Republic of China

3. Center for Outcomes Research and Evaluation Yale–New Haven Hospital New Haven CT

4. Section of Cardiovascular Medicine Yale School of Medicine New Haven CT

5. Department of Internal Medicine Yale School of Medicine New Haven CT

6. Department of Health Policy and Management Yale School of Public Health Yale University New Haven CT

7. Division of Cardiology University of Colorado Anschutz Medical Campus Aurora CO

8. Department of Laboratory Medicine Yale School of Medicine New Haven CT

9. Department of Biostatistics Yale School of Public Health Yale University New Haven CT

Abstract

Background Traditional Chinese medicine ( TCM ) is used in the treatment of many conditions, including heart failure ( HF ), although it is not well characterized. Methods and Results We conducted a retrospective analysis of TCM use in a random sample of hospitalizations for HF within a random sample of Western medicine hospitals in China in 2015 using data from the China PEACE 5r‐HF (China Patient‐Centered Evaluative Assessment of Cardiac Events 5 Retrospective Heart Failure Study). We describe the frequency of TCM use and its association with patient characteristics, in‐hospital use of evidence‐based therapies, and hospital characteristics using hierarchical logistic regression models. Finally, we assessed risk‐adjusted in‐hospital bleeding and mortality. Among 10 004 patients hospitalized with HF (median age, 73 years; 48.9% women) from 189 hospitals, 74.7% received TCM (83.3% administered intravenously). The most commonly used agent was Salvia miltiorrhiza (51.2%). Patients with coronary artery disease (odds ratio [ OR] , 1.73; 95% CI , 1.53–1.95) or stroke ( OR , 1.32; 95% CI , 1.15–1.51) were more likely to receive TCM ; there was no correlation with evidence‐based therapy use. Nearly all hospitals (99.4%) used TCM , with substantial variation across hospitals (median OR, 3.29; 95% CI , 2.82–3.76). In‐patient bleeding ( OR , 1.39; 95% CI , 1.03–1.88) and mortality ( OR , 1.36; 95% CI , 1.04–1.79) were higher with Salvia miltiorrhiza, although not with other TCM s. Conclusions In a nationally representative sample of patients hospitalized with acute HF in China, three fourths received TCM . Nearly all hospitals used TCM , although use varied substantially by hospital. Although TCM was not used in lieu of evidence‐based therapies for HF , we found a signal for harm with the most commonly used TCM . Clinical Trial Registration URL : https://www.clinicaltrials.gov . Unique identifier: NCT 02877914.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3